与类风湿性关节炎相关的间歇性肺病中的抗纤维素药物 - 来自全国性队列队列的现实世界数据
Ana Catarina Duarte1, Carlos Marques Gomes2, Margarida Correia3
1Hospital Garcia de Orta, Unidade Local de Saúde Almada-Seixal.
ARP rheumatology
|October 5, 2024
概括
抗纤维素药物有助于稳定类风湿性关节炎相关间歇性肺病 (RA-ILD) 患者的肺功能. 然而,在这个现实研究中,不良事件经常导致治疗中止.
科学领域:
- 肺部病理学 肺部病理学
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 类风湿性关节炎 (RA) 经常导致间歇性肺病 (ILD),这是一种与较高死亡率相关的疾病.
- 抗纤维性药物 (nintedanib,pirfenidone) 已证明在减缓结缔组织疾病相关的ILD进展方面具有有效性.
研究的目的:
- 评估RA-ILD患者抗纤维素治疗的实际有效性和耐受性.
- 分析抗纤维药对肺功能测试 (PFT) 和国家队列中药物持续性的影响.
主要方法:
- 一项观察性多中心研究跟踪了40名RA-ILD患者,这些患者接受了抗纤维素药物治疗.
- 肺功能测试 (PFT) 和不良事件 (AE) 被前性收集.
- 统计分析包括PFT变化的混合效应模型和药物持续性的Kaplan-Meier曲线.
主要成果:
- 抗纤维素使用似乎稳定了强迫生命能力 (FVC) 和肺总容量 (TLC),阻止了以前的下降.
- 尽管进行了处理,但一氧化碳 (DLCO) 的扩散能力继续下降.
- 40%的患者出现了不良事件,导致30%的患者停止使用药物.
结论:
- 实践数据表明,抗纤维素药物可以稳定RA-ILD患者的肺功能 (FVC,TLC).
- 频繁发生的不良事件是一个重大挑战,往往需要停止治疗.
相关概念视频
01:23Rheumatic Heart Disease I: Introduction
3
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
3
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
8
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
8
01:17Drugs Used in Lower Respiratory Disorders: Overview
358
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
358
01:21Rheumatic Heart Disease III: Medical Management
3
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
3
01:20Rheumatic Heart Disease IV: Nursing Management
5
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
5
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117